VR Logo

Exagen Inc. (XGN) download report


Healthcare | Diagnostics Services

Exagen Inc. (XGN) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States.

IPO Date: 19-Sep-2019

CEO, Pres & Director: Mr. Fortunato Ron Rocca

CFO & Corp. Sec.: Mr. Kamal Adawi M.S., MBA

Listing: NASDAQ: XGN

Country: United States

Headquarters: Vista, CA

Website: https://www.exagen.com

Key Facts

Market cap: $94.29 Mln

Revenue (TTM): $23.08 Mln

Earnings (TTM): $-30.91 Mln

Cash: $89.75 Mln

Total Debt: $34.48 Mln

Insider's Holding: 21.35%

Liquidity: Low

52 Week range: $4.15 - 15.44

Shares outstanding: 16,256,100

10 Years Aggregate:

  • CFO: $-101.35 Mln
  • EBITDA: $-121.73 Mln
  • Net Profit: $-144.20 Mln

Stock Performance

Time Period Exagen (XGN) S&P BSE Sensex S&P Small-Cap 600
YTD-51.16-8.71-17.92
1 month10.72-3.11-7.88
3 months-32.38-7.30-13.56
1 Year-62.750.48-17.16
3 Years--10.346.95
5 Years--11.436.30
10 Years--12.1010.29
As on 28-Jun-2022
Year Exagen (XGN) S&P Small-Cap 600 S&P BSE Sensex
2021-11.8925.2721.99
2020-48.039.5715.75